A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2023
The purpose of this study is to assess the safety and immunogenicity of mRNA-1365, an mRNA vaccine targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) and mRNA-1345, an mRNA vaccine targeting RSV, in participants aged 5 months to \<24 months.
Epistemonikos ID: 6170d47c14170dada1290e033f6eb6d6f8b0710e
First added on: Feb 19, 2024